Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 study to evaluate the safety and efficacy of oral upadacitinib compared to subcutaneous dupilumab in children aged 2 to less than 12 years with moderate to severe atopic dermatitis. The study aims to assess adverse events and changes in disease activity, providing significant insights into pediatric treatment options for this condition.
The interventions being tested are upadacitinib, an oral tablet or solution, and dupilumab, a subcutaneous injection. Upadacitinib is already approved for patients aged 12 or older, and this study seeks to extend its use to younger children.
The study is designed as an interventional, randomized, parallel assignment with single masking for outcomes assessors. Its primary purpose is treatment, focusing on comparing the two drugs’ safety and efficacy.
The study began on August 19, 2024, with an estimated primary completion date yet to be announced. The most recent update was submitted on July 21, 2025, indicating ongoing recruitment and progress.
This study could significantly impact AbbVie’s market position, potentially boosting investor confidence if results favor upadacitinib’s efficacy and safety. The study’s outcome may also influence competitive dynamics in the pediatric dermatology market.
The study is ongoing, with further details available on the ClinicalTrials portal.